AxoGen, Inc. (NASDAQ:AXGN) Receives $46.50 Consensus Target Price from Analysts

Shares of AxoGen, Inc. (NASDAQ:AXGN) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $46.50.

AXGN has been the topic of several research reports. Citigroup reaffirmed an “outperform” rating on shares of AxoGen in a report on Wednesday, April 29th. Wells Fargo & Company upped their price objective on AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Canaccord Genuity Group upped their price objective on AxoGen from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. Finally, HC Wainwright upped their price objective on AxoGen from $39.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th.

Insider Activity

In other news, Director Amy Mcbride Wendell sold 1,647 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $42.60, for a total value of $70,162.20. Following the transaction, the director owned 93,826 shares of the company’s stock, valued at $3,996,987.60. This represents a 1.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director John Johnson sold 11,050 shares of the stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $43.26, for a total value of $478,023.00. Following the completion of the transaction, the director directly owned 11,050 shares in the company, valued at approximately $478,023. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 29,041 shares of company stock valued at $1,268,792 in the last 90 days. 2.44% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. MCF Advisors LLC bought a new stake in shares of AxoGen in the 4th quarter valued at $30,000. Aquatic Capital Management LLC increased its position in shares of AxoGen by 287.8% in the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 1,269 shares in the last quarter. Arax Advisory Partners increased its position in shares of AxoGen by 362.4% in the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 819 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of AxoGen in the 4th quarter valued at $36,000. Finally, Kestra Advisory Services LLC bought a new stake in shares of AxoGen in the 4th quarter valued at $39,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Stock Down 0.8%

NASDAQ:AXGN opened at $43.40 on Wednesday. The stock’s fifty day moving average price is $39.69 and its two-hundred day moving average price is $34.81. AxoGen has a 52-week low of $9.22 and a 52-week high of $45.83. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.33 and a current ratio of 7.10. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -67.81 and a beta of 1.12.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%.The firm had revenue of $61.46 million for the quarter, compared to analyst estimates of $57.85 million. On average, analysts anticipate that AxoGen will post -0.37 EPS for the current year.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.